A post hoc analysis found that peripheral lesions beyond conventional ETDRS fields were significantly associated with an increased risk of disease worsening.
After following patients for four years, researchers identified distinct rates of choroidal and ganglion cell layer loss and are advocating for adjusted screening intervals in these populations.
Patients who received PRP before anti-VEGF were more likely to undergo pars plana vitrectomy for vitreous hemorrhage or RD than those treated in the reverse order.
After 12 months of treatment, the diabetic group showed a smaller reduction than those without the disease, suggesting DR may be a potential treatment modifier in those with comorbid nAMD.
One prominent research group endorsed transition to the newer modality for its studies, and clinicians more broadly can feel confident in everyday practice as well.